Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.60 |
| ▸ | PRKACA | P17612 | 1/20 | 0.60 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.60 |
| ▸ | MARK3 | P27448 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.60 |
| ▸ | CLK2 | P49760 | 1/20 | 0.60 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.60 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.60 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.60 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.60 |
| ▸ | MELK | Q14680 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16236958 | 0.84 | DYRK3 (0.60) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL16236518 | 0.84 | DYRK3 (0.57) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL24072614 | 0.83 | SRC (0.54) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL27217950 | 0.82 | DYRK3 (0.55) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL8441851 | 0.81 | DYRK3 (0.54) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL23966901 | 0.81 | ADK (0.48) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL29032350 | 0.81 | DYRK3 (0.41) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL3782622 | 0.81 | DYRK3 (0.59) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL29503447 | 0.81 | DYRK3 (0.59) | DYRK3ROCK2PRKD3MAP4K4PHKG2 | |
| SCHEMBL15983880 | 0.81 | ADORA2A (0.56) | DYRK3ROCK2PRKD3MAP4K4PHKG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| CN-117597346-A | NEK7 inhibitors | 哈利亚治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| CN-115843272-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | DYRK3 580/4885ROCK2 1133/4885PRKD3 224/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | DYRK3 580/4885ROCK2 1133/4885PRKD3 224/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | DYRK3 3229/4885ROCK2 2826/4885PRKD3 774/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | DYRK3 580/4885ROCK2 1133/4885PRKD3 224/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | DYRK3 1271/4885ROCK2 1375/4885PRKD3 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.